An analysis of patients with advanced hepatocellular carcinoma and elevated AFP who received second-line Cyramza showed improved survival, according to data from the phase 3 REACH study. An analysis ...

INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination with paclitaxel in ...

INDIANAPOLIS, June 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA ® ...

Eli Lilly & Company LLY announced that the FDA has approved its cancer drug, Cyramza (ramucirumab) for the first-line treatment of metastatic non-small cell lung cancer (“NSCLC”) in patients with EGFR ...

INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA ® (ramucirumab) in previously untreated ...

Eli Lilly and Company’s LLY announced that a late-stage study evaluating its already approved cancer drug, Cyramza for the second-line treatment of liver cancer met the primary as well as secondary ...

CYRAMZA is being investigated in a broad global development program that has enrolled more than 14,000 patients across more than 100 trials worldwide. These include several studies investigating ...

CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful ...

INDIANAPOLIS, Sept. 12, 2014 -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer. Adding Cyramza ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) recommended the approval of label expansion for Cyramza (ramucirumab) ...

New Gastric Cancer Drug Gets FDA Approval The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha ...